Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis.

Bioavailability Curcumin Curcuminoids Malignant diseases Turmeric clinicaltrials.gov pubmed.gov

Journal

Naunyn-Schmiedeberg's archives of pharmacology

ISSN: 1432-1912

Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol

Pays: Germany

ID NLM: 0326264

Informations de publication

Date de publication:
15 Nov 2023

Historique:

received: 28 09 2023

accepted: 29 10 2023

medline: 15 11 2023

pubmed: 15 11 2023

entrez: 15 11 2023

Statut: aheadofprint

Résumé

Curcumin is an ingredient of the root Curcuma longa, which is responsible for the characteristic yellow color of curcuma. Curcumin is said to have the potential ability to fight malignant diseases and to have an anti-inflammatory effect. In addition, it is used as a dietary supplement. However, one problem with the use of curcumin is its extremely low bioavailability. The aim of this study is to systematically review and critically analyze clinical studies related to the pharmacokinetics (or bioavailability) and to the use of curcumin in the treatment of malignant diseases. The platforms clinicaltrials.gov and PubMed served as the database for the literature research. A total of 293 available studies on curcumin were filtered according to their focus (bioavailability, therapy of malignant diseases) and other criteria (study results, main substance, topic reference, existing disease/other research purpose, reference to malignant diseases). The studies were further analyzed regarding their outcome measures, their design (number of participants, randomization, placebo group, masking, ethical standards, sponsor, primary outcome measures, secondary outcome measures, study bias) and their findings. The analysis failed to convincingly demonstrate that curcumin has a significant, positive effect on the therapy of malignant diseases. Regarding the increase in bioavailability, positive results have been obtained, which are in proximity to the pharmaceutical industry. Independent studies could not achieve increased bioavailability of curcumin. The available reviews in the literature also do not provide convincing evidence for the efficacy of curcumin. Thus, at the time being, the use of curcumin in malignant diseases is not justified scientifically.

Identifiants

DOI: 10.1007/s00210-023-02825-7 PMID: 37966571

pubmed: 37966571

doi: 10.1007/s00210-023-02825-7

pii: 10.1007/s00210-023-02825-7

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Aguilera EC, Vachon A, Plourde M (2022) Comparative pharmacokinetic of curcuminoids formulations with an omega-3 fatty acids monoglyceride carrier: a randomized cross-over triple-blind study. Nutrients 14:5347. https://doi.org/10.3390/nu14245347

doi: 10.3390/nu14245347 pubmed: 36558506 pmcid: 9783836

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharmaceutics 4:807–818. https://doi.org/10.1021/mp700113r

doi: 10.1021/mp700113r

Chung H, Yoon SH, Cho J-Y et al (2021) Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects. CP 59:684–690. https://doi.org/10.5414/CP204058

doi: 10.5414/CP204058

Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499. https://doi.org/10.1158/1078-0432.CCR-08-0024

doi: 10.1158/1078-0432.CCR-08-0024 pubmed: 18628464

Fança-Berthon P, Tenon M, Bouter-Banon SL et al (2021) Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. J Nutrition 151:1802–1816. https://doi.org/10.1093/jn/nxab087

doi: 10.1093/jn/nxab087

Ferguson JJA, Abbott KA, Garg ML (2021) Anti-inflammatory effects of oral supplementation with curcumin: a systematic review and meta-analysis of randomized controlled trials. Nutrition Rev 79:1043–1066. https://doi.org/10.1093/nutrit/nuaa114

doi: 10.1093/nutrit/nuaa114

Hashemi Goradel N, Najafi M, Salehi E et al (2019) Cyclooxygenase-2 in cancer: a review. J Cell Physio 234:5683–5699. https://doi.org/10.1002/jcp.27411

doi: 10.1002/jcp.27411

Howells L, Malhotra Mukhtyar R, Theofanous D et al (2021) A systematic review assessing clinical utility of curcumin with a focus on cancer prevention. Molecular Nutrition Food Res 65:2000977. https://doi.org/10.1002/mnfr.202000977

doi: 10.1002/mnfr.202000977

Karaboğa Arslan AK, Uzunhisarcıklı E, Yerer MB, Bishayee A (2022) The golden spice curcumin in cancer: a perspective on finalized clinical trials during the last 10 years. J Cancer Res Therapeutics 18:19–26. https://doi.org/10.4103/jcrt.JCRT_1017_20

doi: 10.4103/jcrt.JCRT_1017_20

Mansouri K, Rasoulpoor S, Daneshkhah A et al (2020) Clinical effects of curcumin in enhancing cancer therapy: a systematic review. BMC Cancer 20:791. https://doi.org/10.1186/s12885-020-07256-8

doi: 10.1186/s12885-020-07256-8 pubmed: 32838749 pmcid: 7446227

Liu W, Zhai Y, Heng X et al (2016) Oral bioavailability of curcumin: problems and advancements. J Drug Targeting 24:694–702. https://doi.org/10.3109/1061186X.2016.1157883

doi: 10.3109/1061186X.2016.1157883

Saghatelyan T, Tananyan A, Janoyan N et al (2020) Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: a comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomed 70:153218. https://doi.org/10.1016/j.phymed.2020.153218

doi: 10.1016/j.phymed.2020.153218

Schiborr C, Kocher A, Behnam D et al (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58:516–527. https://doi.org/10.1002/mnfr.201300724

doi: 10.1002/mnfr.201300724 pubmed: 24402825

Storka A, Vcelar B, Klickovic U et al (2015) Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. CP 53:54–65. https://doi.org/10.5414/CP202076

doi: 10.5414/CP202076

Thambamroong T, Seetalarom K, Saichaemchan S et al (2022) Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: a double-blind, placebo-controlled randomised phase IIa trial (CurChexia). J Nutri Meta 2022:1–11. https://doi.org/10.1155/2022/5425619

doi: 10.1155/2022/5425619

Tuyaerts S, Rombauts K, Everaert T et al (2019) A Phase 2 study to assess the immunomodulatory capacity of a lecithin-based delivery system of curcumin in endometrial cancer. Front Nutr 5:138. https://doi.org/10.3389/fnut.2018.00138

doi: 10.3389/fnut.2018.00138 pubmed: 30687714 pmcid: 6336921

Zhang C, Li B, Zhang X et al (2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients’ PBMCs: potential role for STAT-3 and NF-κB signaling. J Invest Dermatol 130:2110–2119. https://doi.org/10.1038/jid.2010.86

doi: 10.1038/jid.2010.86 pubmed: 20393484